Magnetic Resonance Spectroscopy Metabolite Analysis in Different Meningioma Subtypes


  • Made Widhi Asih Staff at Radiology Department Universitas Udayana Faculty of Medicine
  • Felicia Nike Radiology Resident. Radiology Department Universitas Udayana – Prof. dr. IGNG Ngoerah Hospital, Bali, Indonesia
  • Putri Ayu Ratnasari Radiology Resident. Radiology Department Universitas Udayana – Prof. dr. IGNG Ngoerah Hospital, Bali, Indonesia



Meningioma subtypes, MR spectroscopy


Meningiomas are one of the most common lesions of the dura, some meningiomas have aggressive and poor prognosis, therefore surgeons need to evaluate them preoperatively for their therapeutic planning. As one of the advanced MR techniques, proton magnetic resonance spectroscopy (MRS) as a non-invasive, quantitative study to estimate metabolites‬ within the ‬tumor. Of all the known metabolites detected by MRS, creatine, glycine, alanine, lactate, choline, glutamine, glutamate, and the glutamine/glutamate complex are believed to be useful in differentiating meningiomas from other tumors and from normal brain.
Case presentation
This study present 3 different cases of patients with meningioma, based on histopathological analysis, they were respectively diagnosed as WHO Grade I Transitional meningioma, WHO Grade II Atypical meningioma and WHO Grade III Recurrent Anaplastic meningioma.
MRS findings in brain tumor would show decrease in NAA and a decrease in Cr, which showed in all of the three cases. In addition, Cho/Cr ratio was also increased, which was the highest ratio in the third case of anaplastic meningioma.
MRS may aid clinician in the diagnostic process as it showed the biochemical content of the lesion, especially Cho/Cr ratio which might be a useful proliferative parameter in anaplastic meningomas compared with the others.


Download data is not yet available.


Porter KR, McCarthy BJ, Freels S, Kim Y, Davis FG. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro-Oncol. 2010 Jun 1;12(6):520–7.

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023 Jan;73(1):17–48.

Lyndon D, Lansley JA, Evanson J, Krishnan AS. Dural masses: meningiomas and their mimics. Insights Imaging. 2019 Dec;10(1):11.

Ohba S, Murayama K, Nishiyama Y, Adachi K, Yamada S, Abe M, et al. Clinical and Radiographic Features for Differentiating Solitary Fibrous Tumor/Hemangiopericytoma From Meningioma. World Neurosurg. 2019 Oct;130:e383–92.

Lin MC, Li CZ, Hsieh CC, Hong KT, Lin BJ, Lin C, et al. Preoperative grading of intracranial meningioma by magnetic resonance spectroscopy (1H-MRS). Motta A, editor. PLOS ONE. 2018 Nov 19;13(11):e0207612.

Torp SH, Solheim O, Skjulsvik AJ. The WHO 2021 Classification of Central Nervous System tumours: a practical update on what neurosurgeons need to know—a minireview. Acta Neurochir (Wien). 2022 Jul 26;164(9):2453–64.

Drappatz J. How useful is chemotherapy for atypical and anaplastic meningiomas? Expert Opin Pharmacother. 2022 Sep 22;23(14):1559–61.

Matsusue E, Inoue C, Tabuchi S, Yoshioka H, Nagao Y, Matsumoto K, et al. Utility of 3T single-voxel proton MR spectroscopy for differentiating intracranial meningiomas from intracranial enhanced mass lesions. Acta Radiol Open. 2021 Apr;10(4):205846012110094.

Yildirim D, Tutar O, Alis D, Kuyumcu G, Bakan S. Cranial Magnetic Resonance Spectroscopy: An Update of Metabolites and a Special Emphasis on Practical Points. Open J Med Imaging. 2014;04(04):163–71.

Pfisterer WK, Nieman RA, Scheck AC, Coons SW, Spetzler RF, Preul MC. Using ex vivo proton magnetic resonance spectroscopy to reveal associations between biochemical and biological features of meningiomas. Neurosurg Focus. 2010 Jan;28(1):E12.

Demir MK, Iplikcioglu AC, Dincer A, Arslan M, Sav A. Single voxel proton MR spectroscopy findings of typical and atypical intracranial meningiomas. Eur J Radiol. 2006 Oct;60(1):48–55.

Cohen BA, Knopp EA, Rusinek H, Liu S, Gonen O. Brain Compression without Global Neuronal Loss in Meningiomas: Whole-Brain Proton MR Spectroscopy Report of 2 Cases. 2005;

Kousi E, Tsougos I, Fountas K, Theodorou K, Tsolaki E, Fezoulidis I, et al. Distinct peak at 3.8 ppm observed by 3T MR spectroscopy in meningiomas, while nearly absent in high-grade gliomas and cerebral metastases. Mol Med Rep. 2012 Apr;5(4):1011–8.

Kumar A, Kaushik S, Tripathi RP, Kaur P, Khushu S. Role of in vivo proton MR spectroscopy in the evaluation of adult brain lesions: our preliminary experience. Neurol India. 2003 Dec;51(4):474–8.

Shiino A, Nakasu S, Matsuda M, Handa J, Morikawa S, Inubushi T. Noninvasive evaluation of the malignant potential of intracranial meningiomas performed using proton magnetic resonance spectroscopy. J Neurosurg. 1999 Dec;91(6):928–34.

Nilkanthe R, Modi M, Trivedi P, Shah A, Shah J. Prospective study of Meningioma & diagnostic validity of MIB-1 index in grading of meningioma.

Additional Files



How to Cite

Asih, M. W., Nike, F., & Ratnasari, P. A. (2022). Magnetic Resonance Spectroscopy Metabolite Analysis in Different Meningioma Subtypes. Indonesian Archives of Biomedical Research, 3(1), 19–25.